Pharmaceutical

Canary Speech Achieves HITRUST e1 Certification Demonstrating Foundational Cybersecurity

HITRUST e1 Certification validates Canary Speech's commitment to foundational cybersecurity controls and information risk management PROVO, Utah, July 10, 2025…

6 months ago

Healthcare BPO Market worth $694.3 billion by 2030 with 10.7% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 10, 2025 /PRNewswire/ -- The global Healthcare BPO Market, valued at US$337.6 billion in 2024 stood at US$417.7…

6 months ago

Shionogi Implements Stibo Systems MDM Solution

AARHUS, Denmark, July 10, 2025 /PRNewswire/ -- Stibo Systems K.K. (headquartered in Aarhus, Denmark; hereinafter "Stibo Systems") is pleased to announce that…

6 months ago

LG Debuts Next-Generation Precision Medical AI

Joint Development Underway: World-Class Precision Medical AI Platform with Vanderbilt University Medical Center SEOUL, South Korea, July 10, 2025 /PRNewswire/ --…

6 months ago

New TriNetX Survey Reveals Biopharma’s Bold Embrace of Real-World Data and Artificial Intelligence–But Warns of Looming Barriers

Real-world data (RWD), artificial intelligence (AI), and patient-centric trial design lead pharma priorities in 2025, but data compatibility, regulatory hurdles,…

6 months ago

Fifty1 AI Labs’ REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership

Pioneering a New Era in Healthcare: AI-Driven Innovation Unlocks Transformative Therapies and Drives Path to $50M ValuationSEATTLE, July 10, 2025…

6 months ago

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics…

6 months ago

Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily…

6 months ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease

Positive Discussion on Path Forward for Registrational ProgramPURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company…

6 months ago